Liver disease kills approximately two million people per annum. Although organ transplant is a viable option to treat disease, many patients are not candidates for this type of treatment or die on the transplant waiting list.
Stimuliver is developing a disruptive liver implant to treat critically failing liver function in humans.
The implant will be placed underneath the skin to ‘top up’ the patient’s reduced liver function. Lab engineered liver tissue will be produced from human stem cells, providing a scalable and renewable source of human liver tissue. The development of the liver implant to clinical grade will provide patients with a renewable treatment option for their disease.
Company Details
- Employees
- 10
- Founded
- 2021
- Address
- Copenhagen N, 2200, Dk
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.stimuliver.bio
- HQ
- Copenhagen N
Stimuliver Questions
Stimuliver's website is https://www.stimuliver.bio
Stimuliver's LinkedIn profile is https://dk.linkedin.com/company/stimuliver
Stimuliver has
10 employees.
View email and phone details for 10
employees at Stimuliver.
Stimuliver's industry is
Biotechnology Research
Stimuliver's top competitors are
Synklino,
Notify Therapeutics,
Sulis Therapeutics,
Celcore,
Bioinnovation Institute,
Adaptvac,
Biolamina,
Autokeybo,
Troya Therapeutics,
Metsystem.
Stimuliver's categories are Biotechnology Research
Stimuliver's founding year is 2021
